See the Full Picture.

Published 11 days ago • loading... • Updated 11 days ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

Summary by Kilgore News Herald

BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of…

2 Articles

2 Articles

All

Left

1

Center

Right

Kilgore News Herald

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of…

11 days ago

Read Full Article

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer.

11 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left1Leaning Right0Center0Last Updated10 days agoBias Distribution

100% Left

Bias Distribution

100% of the sources lean Left

100% Left

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Kilgore News Herald broke the news in 11 days ago on Wednesday, May 28, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics